436 Studies Now Enrolling
An Open-Label, Expanded Access Protocol for Amifampridine Phosphate (3,4- Diaminopyridine Phosphate) Treatment in Patients with Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome and Downbeat Nystagmus
A study for patients with Lambert-Eaton Myasthenic Syndrome (LEMS) using study drug Amifampridine Phosphate
| Sponsor: | Catalyst Pharmaceuticals |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAO6308 |
| U.S. Govt. ID: | NCT02189720 |
| Contact: | Jacqueline Scoon: 212-305-6035 / js4462@cumc.columbia.edu |
Additional Study Information:
This study is for patients with Lambert-Eaton Myasthenic Syndrome (LEMS). The purpose of this study is to provide doctors and their patients access to amifampridine phosphate therapy for their patients with LEMS, CMS or downbeat nystagmus until the product becomes commercially available. The secondary purpose of the study is to assess the long-term safety of amifampridine phosphate in patents.
This study is closed
